Abstract: This invention relates to a depot formulation comprising a biodegradable silica hydrogel composite incorporating a nucleotide or nucleoside analog reverse transcriptase inhibitor, wherein the silica hydrogel composite is obtainable by mixing silica particles comprising said nucleotide or nucleoside analog reverse transcriptase inhibitor and having a maximum diameter of ?1 000 ?m, as such or as a suspension, with silica sol wherein the hydrogel composite is non-flowing and structurally stable when stored at rest and shear-thinning when shear stress is applied by injection. The present invention also relates to use of the depot formulation for treatment of chronic viral infections and prevention of chronic viral reinfection. The present invention further relates to a prefilled syringes comprising said depot formulation.

Abstract: A method for preparing a sol-gel derived SiO2 having a very fast bioresorption rate where a sol-gel derived SiO2 is prepared from a sol comprising water, an alkoxide or inorganic silicate and a lower alcohol using a mineral acid or a base as a catalyst and the sol is aged and dried. The method uses a pH from 1.5 to 2.5, a molar ratio of water to the alkoxide or inorganic silicate of 0.5 to 2.5, a molar ratio of alcohol to the alkoxide or inorganic silicate is ?0.5; and the sol is either let to gel without induced changes of composition and without forced drying of the sol, or a change of composition is induced; and within a time of ?30 minutes, from the induced change forced drying of the sol is carried out or initiated.

Abstract: This invention relates to a depot formulation comprising a biodegradable silica hydrogel composite incorporating a nucleotide or nucleoside analogue reverse transcriptase inhibitor, wherein the silica hydrogel composite is obtainable by mixing silica particles comprising said nucleotide or nucleoside analogue reverse transcriptase inhibitor and having a maximum diameter of ?1 000 ?m, as such or as a suspension, with silica sol wherein the hydrogel composite is non-flowing and structurally stable when stored at rest and shear-thinning when shear stress is applied by injection. The present invention also relates to use of the depot formulation for treatment of chronic viral infections and prevention of chronic viral reinfection. The present invention further relates to a prefilled syringes comprising said depot formulation.

Abstract: This invention relates to a silica hydrogel composite obtainable by mixing silica particles, comprising an encapsulated agent, with a silica sol, wherein obtained hydrogel composite is shear-thinning. The present invention also relates to use of the silica hydrogel composite according to the invention for an injectable, flowing or extrudable formulation. The present invention further relates to a method for preparing the silica hydrogel.

Abstract: This invention relates to a silica hydrogel composite obtainable by mixing silica particles, comprising an encapsulated agent, with a silica sol, wherein obtained hydrogel composite is shear-thinning. The present invention also relates to use of the silica hydrogel composite according to the invention for an injectable, flowing or extrudable formulation. The present invention further relates to a method for preparing the silica hydrogel.

Abstract: A method for storing a water-soluble undissolved silica-based material, optionally with an incorporated functional agent. The method includes immersing the material in an aqueous liquid phase which is initially saturated with a water-soluble silica-based material which is the same or different than the undissolved silica-based material, such that the undissolved silica-based material does not essentially dissolve into the liquid phase during storage, or the proportion of the amount of the initially undissolved silica-based material to the amount of the liquid phase is such that the liquid phase will be saturated or essentially saturated by a dissolved portion of the water-soluble undissolved silica-based material during storage, which dissolved portion of said water soluble undissolved silica-based material is less than 20%. Also disclosed is a storage package which may preferably be used to store functional agents, delivery devices or implants.

Abstract: A method for producing a flowing silica composition including a sol-gel transfer, where redispersion is carried out. The redispersion includes adding, after having reached gel point of the sol-gel transfer, liquid into the gel formed by the sol-gel transfer, and the addition being made within a sufficiently short time period after reaching the gel point, to result, after mixing of the gel and the liquid, in a rheologically homogenous flowing silica composition, which is and remains injectable as such, or by short stirring <30 s, through a thin 22G needle. Also disclosed are flowing silica compositions and gels obtainable by methods of the invention, and uses of flowing silica compositions.

Abstract: A method for preparing controllably biodegradable silica fibres which includes spinning the fibres from a silica sol of controlled viscosity, controllably biodegradable silica fibres prepared according to the method, methods for controlling the biodegradability of the fibres, the use of controllably biodegradable fibres as sustained and/or controlled release delivery devices for biologically active agents, and pharmaceutical preparations containing such devices.

Abstract: A biodegradable carrier is produced for preservation and/or controlled delivery of biologically active agents where said biodegradable carrier is a silica xerogel which is made from water and silane by using acid or base as a catalyst, and biologically active agents in said biodegradable carrier are infecting and/or transfecting viruses. Silica xerogel material can be pharmaceutically acceptable and it can be used as a medicine.

Abstract: A biodegradable carrier is produced for preservation and/or controlled delivery of biologically active agents where the biodegradable carrier is a silica xerogel which is made from water and silane by using acid or base as a catalyst, and biologically active agents in the biodegradable carrier are infecting and/or transfecting viruses. Silica xerogel material can be pharmaceutically acceptable and it can be used as a medicine.

Abstract: Controllably dissolvable silica-xerogels prepared via sol-gel process and their use. A delivery device including controllably dissolvable silica-xerogel into which structure a biologically active agent is incorporated. Pharmaceutical preparations including this device. Medical devices for orthopedic and surgical purposes which contain controllably dissolvable silica-xerogels, which may further include a biologically active agent.

Abstract: A composition for controlled release of a biologically active agent from a carrier. The biologically active agent is heparin or a related biologically active acidic polysaccharide and the carrier is a sol-gel derived silica xerogel. The xerogel is derived from a tetraalkoxysilane such as tetrethoxysilane (TEOS) and part of the tetraalkoxysilane is replaced by an organomodified alkoxysilane, preferably an akylsubsitituted alkoxysilane. The invention also includes a method for the preparation of this composition.

Abstract: A material for medical use in humans and/or animals bearing a biologically active agent, the material being multilayered, as well as a device of this material and a method to produce it. The material includes a core material, where the core material is formed into a body, optionally having the shape of a finished device; two or more layers of coating material of which the first layer has been applied onto the core material and additional layers have been applied onto the coating material of a preceding layer; and where at least one of the layers includes the biologically active agent. A feature of this invention is that the coating material is a biopolymer, a sol-gel produced silica gel or a biologically active molecule.

Abstract: Controllably dissolvable silica-xerogels prepared via sol-gel process and their use. A delivery device including controllably dissolvable silica-xerogel into which structure a biologically active agent is incorporated. Pharmaceutical preparations including this device. Medical devices for orthopedic and surgical purposes which contain controllably dissolvable silica-xerogels, which may further include a biologically active agent.